Sublingual medical cannabis tablets have been exported to France as part of the country’s trial to regulate the industry.
The export marks the first from Israel to France as part of the French government and the French National Agency for the Safety of Medicines and Health Products (ANSM) programme.
The programme was launched in March 2021 and includes about 3000 patients who are receiving medical cannabis in France for the first time. Indications included under the programme are cancer, epilepsy, Multiple Sclerosis (MS), palliative care and pain that does not respond to conventional treatment.
The tablets, Naxiva-Panaxir, which will enable physicians to provide a more precise treatment routine to the patients, will be issued to patients participating in the programme in hospitals and pharmacies across the country.
CEO of Panaxia Israel, Dr Dadi Segal, commented: “We are glad of another significant milestone in the implementation of our strategy. We are proud to be, alongside our partner, Neuraxpharm, part of the spearhead of the world’s leading cannabis key players selected for the ANSM programme.
Read more: Panaxia to exit cannabis activities in Israel and focus on Europe
“In addition, we are the only company in this programme to supply medical cannabis sublingual tablets. According to our predictions, the French market is expected to become one of the most advanced medical cannabis markets in the world, which will be a remarkable growth engine for Panaxia.”
The export follows the issue of Panaxia Labs and Neuraxpharm’s premium oils to patients in the country, also as part of the ANSM programme.
General manager of Neuraxpharm France, Dr Pierre-Hervé Brun, said: “It is a great achievement for us, together with our partner Panaxia, to have been selected as one of the few specialists offering medical cannabis on the French market under the ANSM programme.
Read more: First retail sales in Europe for vaporisation extracts completed
“As the only companies in the programme providing medical cannabis sublingual tablets, we are able to offer our patients a variety of patient-oriented and more easy-to-use forms of presentation.
“Going forward, we will continue to work with Panaxia to pursue our strategy in the fast-growing medical cannabis sector and bring more in-demand dosage forms and treatments to market.”
In August 2021 Panaxia and Neuraxpharm signed an agreement to distribute advanced medical cannabis products in Poland. Additionally, Panaxia, which recently announced it would be exiting activities in Israel to focus on Europe, signed an agreement with German-based AxioNovo to export its medical cannabis products into Germany.
[activecampaign form=31]
